These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 15759169)

  • 21. A comparison of utility measurement using EQ-5D and SF-6D preference-based generic instruments in patients with rheumatoid arthritis.
    Salaffi F; Carotti M; Ciapetti A; Gasparini S; Grassi W
    Clin Exp Rheumatol; 2011; 29(4):661-71. PubMed ID: 21813061
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reconsidering the use of rankings in the valuation of health states: a model for estimating cardinal values from ordinal data.
    Salomon JA
    Popul Health Metr; 2003 Dec; 1(1):12. PubMed ID: 14687419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of age on health state valuations.
    Dolan P
    J Health Serv Res Policy; 2000 Jan; 5(1):17-21. PubMed ID: 10787582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of contemporaneous EQ-5D and SF-6D responses using scoring algorithms derived from similar valuation exercises.
    Whitehurst DG; Norman R; Brazier JE; Viney R
    Value Health; 2014 Jul; 17(5):570-7. PubMed ID: 25128050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance of the EQ-5D in patients with irritable bowel syndrome.
    Bushnell DM; Martin ML; Ricci JF; Bracco A
    Value Health; 2006; 9(2):90-7. PubMed ID: 16626412
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Social valuation of EQ-5D health states: the Chilean case.
    Zarate V; Kind P; Valenzuela P; Vignau A; Olivares-Tirado P; Munoz A
    Value Health; 2011 Dec; 14(8):1135-41. PubMed ID: 22152184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is there a case for using visual analogue scale valuations in cost-utility analysis?
    Parkin D; Devlin N
    Health Econ; 2006 Jul; 15(7):653-64. PubMed ID: 16498700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An Empirical Study of Two Alternative Comparators for Use in Time Trade-Off Studies.
    Shah K; Mulhern B; Longworth L; Janssen MF
    Value Health; 2016 Jan; 19(1):53-9. PubMed ID: 26797236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A "new and improved" EQ-5D valuation questionnaire? Results from a pilot study.
    Devlin N; Hansen P; Herbison P; Macran S
    Eur J Health Econ; 2005 Mar; 6(1):73-82. PubMed ID: 15586307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Valuation of preference-based measures: can existing preference data be used to generate better estimates?
    Kharroubi SA
    Health Qual Life Outcomes; 2018 Jun; 16(1):116. PubMed ID: 29866108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Valuing Health States in Russia: A First Feasibility Study.
    Khabibullina A; Gerry CJ
    Value Health Reg Issues; 2019 Sep; 19():75-80. PubMed ID: 31181452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. QALY weights for diabetic retinopathy--a comparison of health state valuations with HUI-3, EQ-5D, EQ-VAS, and TTO.
    Heintz E; Wiréhn AB; Peebo BB; Rosenqvist U; Levin LÅ
    Value Health; 2012 May; 15(3):475-84. PubMed ID: 22583458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The responsiveness of EQ-5D utility scores in patients with depression: A comparison with instruments measuring quality of life, psychopathology and social functioning.
    Günther OH; Roick C; Angermeyer MC; König HH
    J Affect Disord; 2008 Jan; 105(1-3):81-91. PubMed ID: 17532051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chinese time trade-off values for EQ-5D health states.
    Liu GG; Wu H; Li M; Gao C; Luo N
    Value Health; 2014 Jul; 17(5):597-604. PubMed ID: 25128053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Valuing the Child Health Utility 9D: Using profile case best worst scaling methods to develop a new adolescent specific scoring algorithm.
    Ratcliffe J; Huynh E; Chen G; Stevens K; Swait J; Brazier J; Sawyer M; Roberts R; Flynn T
    Soc Sci Med; 2016 May; 157():48-59. PubMed ID: 27060541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using the Multiple Sclerosis Impact Scale to estimate health state utility values: mapping from the MSIS-29, version 2, to the EQ-5D and the SF-6D.
    Hawton A; Green C; Telford C; Zajicek J; Wright D
    Value Health; 2012 Dec; 15(8):1084-91. PubMed ID: 23244811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Unchained melody: revisiting the estimation of SF-6D values.
    Craig BM
    Eur J Health Econ; 2016 Sep; 17(7):865-73. PubMed ID: 26359242
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Valuation of EQ-5D health states in Poland: first TTO-based social value set in Central and Eastern Europe.
    Golicki D; Jakubczyk M; Niewada M; Wrona W; Busschbach JJ
    Value Health; 2010; 13(2):289-97. PubMed ID: 19744296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A value set for the EQ-5D based on experienced health states: development and testing for the German population.
    Leidl R; Reitmeir P
    Pharmacoeconomics; 2011 Jun; 29(6):521-34. PubMed ID: 21247225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transforming discrete choice experiment latent scale values for EQ-5D-3L using the visual analogue scale.
    Webb EJD; O'Dwyer J; Meads D; Kind P; Wright P
    Eur J Health Econ; 2020 Jul; 21(5):787-800. PubMed ID: 32180068
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.